Boswellia (Shallaki) Capsules – Joints Support
- Reviews (4)
|Ingredients:||Refer to Ingredients Section|
|Qty:||60 Veg Capsules|
|Suggested usage:||1 Capsule twice daily after meals or as directed by the physician|
Morpheme Shallaki is an excellent herbal remedy for maintaining an effective joint health and pain management. It takes care of the skeleton and joint muscles in the body. Shallaki or Boswellia Serrata has been used widely for thousands of years to support joints.
Shallaki supplements are used extensively as an anti-arthritic and anti-inflammatory product. Due to its anti-inflammatory property, it is used for alleviating the symptoms of fibrositis, osteoarthritis, rheumatoid arthritis, myositis, low back pain and gout. The therapeutic property of Shallaki includes decrease in swelling, joint restoration and enhancement of blood-supply to increased mobility, inflamed joints, amelioration and pain relief.
- Helps to reduce inflammation of joints, hence beneficial for arthritis patients
- Safe, powerful and all natural dextoxifier
- Helps clean blood vessels, break down and clear cholesterol buildup
- Supports the natural inflammation response of the body
- Helps in reducing body weight
- Provides soothing and relaxing effect
- Offers a wide-range of immunomodulating and health properties
- Supports comfortable and normal range of movement
How to use
Morpheme Shallaki capsules to be taken 2 times per day. Although, the product is tolerated by a good number of users, in a few rare cases the side-effects can range from nausea to diarrhea to rashes.
How Shallaki is Useful?
Boswellia serrata or shallaki is a moderate to large branching tree that is used in the traditional Ayurvedic system as an expectorant, stimulant, antiseptic, astringent and antiarthritic. Some of the active constituents of Boswellia include volatile oils, sugars, and terpenoids. About 16% of resin is made up of essential oil and the majority being p-cymene and alpha-thujene. Four pentacyclic-triterpene acids and beta-boswellic acids are the major constituents of the herb.
Inflammatory Bowel Disease
An animal study carried out to determine the effectiveness of the extract of Shallaki and acetyl-11-keto-β-boswellic acid (one of the constituents in the herb) on leukocyte-endothelial-cell interactions in case of inflammatory bowel disease was stimulated in Sprague-Dawley rats through indomethacin, the subcutaneous injection. Two different doses (high or low) of AKBA or Boswellia were given to the rodents or placebo. The result showed that the extract of Shallaki and the potency of AKBA reduced rolling up to 90% and up to 98% of adherent leukocytes eased tissue injury scores. There was significant reduction in microscopic and macroscopic swelling of the gut-mucosa.
A major role is played by the leukotrienes in the inflammatory procedure of ulcerative colitis. The effect of shallaki extract (350 mg 3 times a day) was compared to the compound sulfasalazine (one gram 3 times a day) in patients suffering from ulcerative colitis. There was improvement in patients, who were taken Boswellia extract than in patients, who were on sulfasalazine. Almost 82% of patients were into remission, when compared to 75% on sulfasalazine. Further study conducted on patients with chronic colitis taking gum-resin of Shallaki (900 mg every day in 3 equally divided dosages for 6 weeks) and the compound sulfasalazine (3 gram every day in 3 divided dosages for 6 weeks) showed similar progress. In addition, 14 of 20 participants who took Shallaki gum resin throughout the study period experienced significant diminution of the symptoms of the disease as compared to 4 out of 10 patients who took sulfasalazine.
A study was conducted in the year 1998 to check the effects of Boswellia Serrata on the bronchial asthma. About 40 patients took Boswellia (300 mg) preparation 3 times every day for 6 weeks, while about 40 people took a placebo. Almost 70% of the patients taking the herb demonstrated disease improvement, and objective progress in immune and lung function. Only 27% of them taking placebo showed improvement.
In a placebo-controlled double-blind trial, Shallaki showed beneficial effect on osteoarthritis. About thirty participants were given Boswellia (1000 mg) or placebo in 3 doses for about 8 weeks. The Boswellian group patients showed a significant reduction in swelling and pain as compared to patients in placebo. In another crossover placebo-controlled double-blind study, Shallaki in combination with other herbs turmeric, ashwagandha and the mineral zinc was studied on patients with osteoarthritis. 44 patients received either placebo or herbal-mineral formulation for 3 months and then switched to another protocol after a fifteen day period for 3 months. The participants in the clinical study who took the herbal-mineral preparation experienced considerable reduction in pain compared to placebo.